Inhalant Allergy Tests
Posted by Health articles on June 3rd, 2009
The in vitro serum tests employ specific antisera, and the allergen antibody reactions are amplified as a radioimmunoassay (RAST), fluorescent immunoassay (FAST), or an enzyme-linked immunosorbent assay (ELISA). Each of these techniques is comparable when performed properly. In vitro tests are acceptable substitutes for skin tests in the following circumstances:
1) The patient has abnormal skin, such as dermatographism or extensive dermatitis,
2) The patient cannot or did not discontinue antihistamines or other interfering medications,
3) The patient is very allergic by history, and anaphylaxis is a possible risk, and
4) The patient is noncompliant regarding skin testing. The results of either skin tests or in vitro assays depend very much on the quality of the allergen and the competence with which the
test is performed.
A typical radioimmunoassay:

Although the quality of allergens is improving, there is need for more and better standardization. Both skin testing and in vitro assays have been criticized for lack of good quality control. Skin testing should not be an occasional test for the inexperienced and obviously never should be delegated to an inadequately trained or unsupervised assistant. Board certified allergy and immunology specialists are best qualified to correlate patient histories with tests results. Quality control also has been a major problem for in vitro serum IgE antibody tests.
Compulsory participation in quality control programs, such as that offered by the College of American Pathologists and mandated by the Clinical Laboratory Improvement Act, eventually will lead to better quality and standardization of in vitro serum IgE tests.
Positive tests for allergen-specific IgE do not diagnose allergy; they only indicate the presence of IgE molecules that have a particular immunologic specificity. Whether the specific IgE antibodies are responsible for clinically apparent disease must be determined by a well-trained physician. The ultimate standard for the diagnosis of allergic disease remains the combination of: a positive history, the presence of specific IgE antibodies, and demonstration that the symptoms are the result of IgE-mediated inflammation.
To avoid false-negative skin tests, short-acting antihistamines should be withheld for 36 to 48 hours and long-acting antihistamines (ie, astemizole) for 4 to 6 weeks before skin tests are performed because antihistamines suppress skin testing results. The specifics of skin testing are outlined in standard allergy textbooks. Skin tests with the appropriate allergens are mandatory in all patients prior to initiation of immunotherapy with allergy extracts, and the intensity of the local wheal and flare skin reactions is a guide for determining the initial dose of allergen.
Skin testing by the multiple serial dilution (end-point titration method) is not recommended by this author because multiple skin tests increase the cost of evaluating the patient and the postulated more quantitative results have not been validated. Sublingual challenge with allergen is not a useful diagnostic test for inhalant allergy, and so-called neutralization of allergy via sublingual drops of allergen has not been substantiated. In vitro cytotoxic leukocyte test has not been documented as a useful laboratory test in controlled studies and is not recommended.